Syremis Therapeutics
Novel Therapies for Neuropsychiatric Conditions
Company Overview
Snapshot
Founded in April 2025 by Elisabeth Kogan, Elena Kagan, and Menashe Levy, Syremis Therapeutics operates with 11–50 employees. The company has raised $165 million across one funding round from 6 investors. In December 2025, Syremis Therapeutics launched with a significant $165 million Series A funding round to advance its pipeline of mental health treatments.
Business overview
Syremis Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for neuropsychiatric conditions. The company's core technology leverages emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism, to address mental health challenges. Syremis Therapeutics operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries.
Strategic signal
In December 2025, Syremis Therapeutics launched with a substantial $165 million Series A funding round, signaling strong investor confidence in its approach to mental health treatment. This significant capital infusion positions the company to accelerate the development of its neuropsychiatric pipeline, which is rooted in novel mechanisms for conditions like schizophrenia, and indicates a strategic push towards clinical validation and market entry for its therapies.
Company Intelligence Q&A
- When was Syremis Therapeutics founded and by whom?
- Syremis Therapeutics was founded in April 2025 by Elisabeth Kogan, Elena Kagan, and Menashe Levy.
- What significant funding did Syremis Therapeutics announce recently?
- In December 2025, Syremis Therapeutics launched with a $165 million Series A funding round. This round was led by Dexcel Pharma and Third Rock Ventures.
- What is the primary focus of Syremis Therapeutics' drug development?
- Syremis Therapeutics is focused on developing novel medicines for neuropsychiatric conditions, with a pipeline rooted in mechanisms such as muscarinic M1/M4 agonism and next-generation NMDA antagonism.
- How many employees does Syremis Therapeutics have?
- Syremis Therapeutics has 11–50 employees.
- What is the current product stage of Syremis Therapeutics?
- Syremis Therapeutics' products are currently in the Clinical Trial stage, focusing on advancing its pipeline of mental health treatments, including those for schizophrenia.